Details of the Drug Combination

General Information of Drug Combination (ID: DC0N8UC)

Drug Combination Name
Pizotyline BRL-15572
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Pizotyline   DMV74ZH BRL-15572   DMM61Y2
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 7.1
Bliss Independence Score: 7.1
Loewe Additivity Score: 22.41
LHighest Single Agent (HSA) Score: 22.41

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Pizotyline
Disease Entry ICD 11 Status REF
Headache 8A80-8A84 Approved [2]
Pizotyline Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
5-HT receptor (5HTR) TT85JO3 NOUNIPROTAC Modulator [4]
------------------------------------------------------------------------------------
Pizotyline Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
UDP-glucuronosyltransferase 2B10 (UGT2B10) DEI8NGH UDB10_HUMAN Metabolism [5]
------------------------------------------------------------------------------------
Pizotyline Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Decreases Activity [6]
------------------------------------------------------------------------------------
Indication(s) of BRL-15572
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [3]
BRL-15572 Interacts with 9 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
5-HT 1B receptor (HTR1B) TTK8CXU 5HT1B_HUMAN Agonist [7]
5-HT 1D receptor (HTR1D) TT6MSOK 5HT1D_HUMAN Agonist [7]
5-HT 6 receptor (HTR6) TTJS8PY 5HT6R_HUMAN Agonist [7]
5-HT 2B receptor (HTR2B) TT0K1SC 5HT2B_HUMAN Agonist [7]
5-HT 2A receptor (HTR2A) TTJQOD7 5HT2A_HUMAN Agonist [7]
5-HT 1F receptor (HTR1F) TT0MI3F 5HT1F_HUMAN Agonist [7]
5-HT 1A receptor (HTR1A) TTSQIFT 5HT1A_HUMAN Agonist [7]
5-HT 2C receptor (HTR2C) TTWJBZ5 5HT2C_HUMAN Agonist [7]
5-HT 1E receptor (HTR1E) TTCPG9S 5HT1E_HUMAN Agonist [7]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 DTT(s)

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 93).
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 10).
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 Human UDP-glucuronosyltransferase (UGT) 2B10 in drug N-glucuronidation: substrate screening and comparison with UGT1A3 and UGT1A4. Drug Metab Dispos. 2013 Jul;41(7):1389-97.
6 Why are most phospholipidosis inducers also hERG blockers?. Arch Toxicol. 2017 Dec;91(12):3885-3895. doi: 10.1007/s00204-017-1995-9. Epub 2017 May 27.
7 SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20.